Atai Looks To Step Away From Ketamine Study After Posting Positive Results

August 9, 2023 · Green Market Report

Atai Life Sciences (NASDAQ: ATAI) announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). The small study seemed to deliver positive results, but it also looks as if Atai needs a partner before moving forward with the drug.

The study enrolled 16 healthy volunteers, each into one of four sequences of administration. The Phase 1 open-label, 4-period crossover study assessed the safety, tolerability, and pharmacokinetic profile of 60mg, 90mg and 120mg of PCN-101 delivered subcutaneously as compared to 60mg of PCN-101 delivered intravenously.

The study was designed to inform dosing regimens with the goal of creating an at-home use of ketamine versus going to a clinic for an IV treatment.

Positive Results

Atai said in its statement that the pharmacokinetic (PK) analysis indicated that 120mg of PCN-101 delivered SQ resulted in an approximate doubling of drug exposure (AUC) while maintaining approximately the same maximum concentration (Cmax) as the 60mg IV dose. It was generally well-tolerated with no serious adverse events reported.

At the 60mg IV dose, rates of sedation and dissociation were consistent with prior studies of PCN-101 at this dose-level. Encouragingly, at the highest SQ dose of 120mg, rates of sedation (defined as MOAA/S1 score <5) and dissociation (defined as CADSS2 total score >4 and change from baseline >0) were each 14%.

Spravato Comparisons

Atai said, “While recognizing the limitations of this small bridging study and cross-trial comparisons, this safety and tolerability profile compares favorably to that of Spravato, for which rates of sedation and dissociation have been reported to be in the ranges of 50-61% and 61-69%3, respectively, in prior studies. In addition, rates of sedation and dissociation were similar to those seen in the placebo arms of both the prior Phase 2 study of PCN-101 and the Spravato clinical trials in depression. Collectively, we believe these data support the concept of at-home use of PCN-101 in future studies.”

It was the last line of the press release that stood out with Atai saying it continues to work with Perception Neuroscience to explore strategic partnership options. This indicated to investors that the company wasn’t able to support funding the study program.

Investors weren’t happy with this news. The stock opened at $1.77 on Tuesday when the results were announced, but closed down at $1.75. Trading was active with 1.3 million shares, one of the largest days since mid-July. (Full Story)

In categories:Psychedelics Research
Next Post

States with Recreational Cannabis See a Reduction in Mental Health Treatments Says New Study

States With Legal Recreational Weed See A Reduction In Mental Health Treatment New Study Shows Other Positive Benefits Of Adult Use Laws Marijuana is not only a safe drug, it benefits society as a whole. There have been several studies pointing to…
Read
Previous Post

Minnesota Psychedelics Task Force Takes Shape, But Key Appointments And First Meeting Delayed

A Minnesota government psychedelics task force is being built out to prepare the state for the possible legalization of substances like psilocybin and ibogaine. But even though appointments to the panel are behind schedule and it missed a deadline to hold…
Read
Random Post

Ohio Gets Ready to Legalize Recreational Cannabis After They Like What They See in Their Medical Marijuana Program

Should a bipartisan bill receive approval from the Ohio Statehouse, individuals in Ohio who are 21 years old and above will gain the right to cultivate, purchase, and possess marijuana. State representatives Casey Weinstein of Hudson and Jamie Callender of…
Read
Random Post

NFL Is Putting More Money Into Research On CBD As An Opioid Alternative For Players With Concussions

The National Football League (NFL) and its players union announced on Thursday that they are jointly awarding another round of funding to support independent research on the therapeutic benefits of CBD as a pain treatment alternative to opioids for players…
Read
Random Post

You Can’t Judge a Book by Its Cover … or Can You?

“You can’t judge a book by its cover.” I can vouch for that. I’ve read some truly terrible books encased in gorgeous jackets. Sadly, I’m not alone in letting my eyes overrule my intellect. Research has shown that after the…
Read
Random Post

The Illegal Cannabis 'Whack-A-Mole' Problem Finally Solved? - NYC to Go After Landlords That Rent to Illegal Weed Shops

Lynn C. Schulman, a councilman for New York City, filed a measure in April 2023 that would make it illegal for landlords to lease to business tenants who are engaged in the unauthorised sale of cannabis. On Thursday, June 22, the bill…
Read